Nature Medicine, Published online: 29 May 2025; doi:10.1038/d41591-025-00034-8
GLP-1 receptor agonist semaglutide significantly outperformed placebo in an ongoing phase 3 trial, showing reductions in steatohepatitis and liver fibrosis, in addition to cardiometabolic benefits.
